PDF(Pubmed)
Abstract：
UNASSIGNED: Mucormycosis emerged as a wildfire in post-covid-19 infected patients. Most frequently involved sites of mucormycosis are rhino-orbital, rhino-sinusal and rhino-orbito-cerebral. The hallmark sign of mucormycosis is tissue necrosis, which is often a late sign. The fatality rate of mucormycosis is 46% globally. Despite early aggressive combined surgical and medical therapy, the prognosis of mucormycosis is poor.
UNASSIGNED: We searched the electronic database of PubMed, web of science, Embase, Scopus and Google Scholar from Jan 2020 until December 2021 using keywords. We retrieved all the granular details of original research articles, case reports/series of patients with rhino-orbito-cerebral mucormycosis (ROCM), and COVID-19 reported worldwide. Subsequently, we analyzed the patient characteristics, associated comorbidities, location of mucormycosis, treatment given and its outcome in people with COVID-19. (Prospero registration-CRD42021256830, June 4, 2021).
UNASSIGNED: Overall, 544 rhino-orbito-cerebral mucormycosis patients were included in our review with a history of Covid-19 infection. Out of which 410 patients had diabetes mellitus which has proven to be major contributing immunocompromised disease. Other diseases like hypertension, chronic kidney diseases, hypothyroidism, etc., were also attributed as an immunocompromised disease causing increased number of covid associated mucormycosis cases. We found out that total number of patients alive after taking only antifungal drug treatment were 25 in number, whereas total number of patients alive when antifungal drugs were combined with surgical intervention were 428 which was significantly higher.
UNASSIGNED: Our systematic review concluded that surgical debridement should be performed whenever feasible in parallel to antifungal treatment in order to reduce the mortality rate of COVID-19 associated rhino-orbito-cerebral mucormycosis patients.
UNASSIGNED: We searched the electronic database of PubMed, web of science, Embase, Scopus and Google Scholar from Jan 2020 until December 2021 using keywords. We retrieved all the granular details of original research articles, case reports/series of patients with rhino-orbito-cerebral mucormycosis (ROCM), and COVID-19 reported worldwide. Subsequently, we analyzed the patient characteristics, associated comorbidities, location of mucormycosis, treatment given and its outcome in people with COVID-19. (Prospero registration-CRD42021256830, June 4, 2021).
UNASSIGNED: Overall, 544 rhino-orbito-cerebral mucormycosis patients were included in our review with a history of Covid-19 infection. Out of which 410 patients had diabetes mellitus which has proven to be major contributing immunocompromised disease. Other diseases like hypertension, chronic kidney diseases, hypothyroidism, etc., were also attributed as an immunocompromised disease causing increased number of covid associated mucormycosis cases. We found out that total number of patients alive after taking only antifungal drug treatment were 25 in number, whereas total number of patients alive when antifungal drugs were combined with surgical intervention were 428 which was significantly higher.
UNASSIGNED: Our systematic review concluded that surgical debridement should be performed whenever feasible in parallel to antifungal treatment in order to reduce the mortality rate of COVID-19 associated rhino-orbito-cerebral mucormycosis patients.
摘要：
■毛霉菌病在covid-19感染后的患者中作为野火出现。毛霉菌病最常见的部位是犀牛眼眶，犀牛-鼻窦和犀牛-大脑。毛霉菌病的标志是组织坏死，这往往是一个迟到的迹象。全球毛霉菌病的死亡率为46%。尽管早期积极的联合手术和药物治疗，毛霉菌病的预后较差。
■我们搜索了PubMed的电子数据库，科学网,Embase,Scopus和GoogleScholar从2020年1月到2021年12月使用关键字。我们检索了原始研究文章的所有细节，病例报告/系列患者为犀牛脑毛霉菌病（ROCM），和COVID-19在全球范围内报告。随后，我们分析了病人的特点,相关的合并症，毛霉菌病的位置，COVID-19患者的治疗及其结果。（Prospero注册-CRD42021256830，2021年6月4日）。
■总的来说，我们的审查中包括了544例有Covid-19感染史的犀牛或脑毛霉菌病患者。其中410名患者患有糖尿病，已被证明是主要的免疫功能低下疾病。其他疾病，如高血压，慢性肾脏疾病,甲状腺功能减退,等。,也被认为是一种免疫受损的疾病，导致covid相关的毛霉菌病病例数量增加。我们发现，仅服用抗真菌药物治疗后存活的患者总数为25，而当抗真菌药物联合手术干预时，存活的患者总数为428，这一比例明显更高。
■我们的系统评价得出的结论是，应在可行的情况下进行手术清创，同时进行抗真菌治疗，以降低COVID-19相关犀牛或脑毛霉菌病患者的死亡率。
■我们搜索了PubMed的电子数据库，科学网,Embase,Scopus和GoogleScholar从2020年1月到2021年12月使用关键字。我们检索了原始研究文章的所有细节，病例报告/系列患者为犀牛脑毛霉菌病（ROCM），和COVID-19在全球范围内报告。随后，我们分析了病人的特点,相关的合并症，毛霉菌病的位置，COVID-19患者的治疗及其结果。（Prospero注册-CRD42021256830，2021年6月4日）。
■总的来说，我们的审查中包括了544例有Covid-19感染史的犀牛或脑毛霉菌病患者。其中410名患者患有糖尿病，已被证明是主要的免疫功能低下疾病。其他疾病，如高血压，慢性肾脏疾病,甲状腺功能减退,等。,也被认为是一种免疫受损的疾病，导致covid相关的毛霉菌病病例数量增加。我们发现，仅服用抗真菌药物治疗后存活的患者总数为25，而当抗真菌药物联合手术干预时，存活的患者总数为428，这一比例明显更高。
■我们的系统评价得出的结论是，应在可行的情况下进行手术清创，同时进行抗真菌治疗，以降低COVID-19相关犀牛或脑毛霉菌病患者的死亡率。
